Adult dating velocity
Details regarding the event webcast will be announced prior to the event.Analysts and investors may email [email protected] more information or to RSVP.
Please refer to the deadline dates posted next to the city in which you are attending.About Somavaratan Somavaratan is investigational, novel, long-acting form of recombinant human growth hormone (rh GH).This fusion protein consists of rh GH and specific sequences of naturally-occurring hydrophilic amino acids based on a proprietary XTEN®technology.is an endocrine-focused biopharmaceutical company initially developing somavaratan, a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults.Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please select the "back" button in your browser and try again.
(NASDAQ: VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rh GH) for growth hormone deficiency (GHD), today announced the completion of enrollment in the Phase 3 VELOCITY trial of somavaratan in pediatric GHD.
• Velocity will credit appropriate room night / tax charges to your hotel master bill.
Hotel reservations should be made through the host hotel under the studio director’s name for discount to apply.• In order to receive discounts, all students accounted for must be paying full price and be registered before the deadline of the city in which you are attending.
As with patients who completed the prior Phase 2 trial of somavaratan in pediatric GHD, patients completing the Phase 3 VELOCITY trial will have the opportunity to transition to an ongoing, open-label, long-term safety study named VISTA ( Annual Meeting in Q2 2016.
Somavaratan's twice-monthly dosing schedule is the least frequent dosing interval in development for long-acting growth hormones.
Somavaratan has been designed with the goal of improving therapeutic outcomes for children and adults with growth hormone deficiency (GHD), including enhanced compliance and convenience with a twice-monthly dosing schedule, fine gauge needle autoinjector device and room temperature storage.